Personal information

Other IDs

Scopus Author ID: 57199155555
ResearcherID: AAY-9750-2020

Countries

United States

Activities

Collapse all

Employment (1)

City of Hope: Duarte, CA, US

2014-08-01 to present | Associate Professor (Hematology and Hematopoietic Cell Transplantation)
Employment
Source: Self-asserted source
Matthew Mei

Education and qualifications (4)

City of Hope: Duarte, US

2011-07-01 to 2014-06-30 | Fellowship (Hematology/Oncology)
Education
Source: Self-asserted source
Matthew Mei

UCSF Medical Center: San Francisco, CA, US

2010 | Internal Medicine Residency
Education
Source: Self-asserted source
Matthew Mei

Case Western Reserve University School of Medicine: Cleveland, OH, US

2003 to 2007 | MD
Education
Source: Self-asserted source
Matthew Mei

Harvard University: Cambridge, MA, US

1999-09-01 to 2003-06-30 | A.B.
Education
Source: Self-asserted source
Matthew Mei

Funding (1)

The Impact of Somatic Mutations on Allogeneic Transplantation Outcomes in Chronic Myelomonocytic Leukemia

Grant
Leukemia Research Foundation (Northfield, IL, US)
Source: Self-asserted source
Matthew Mei

Peer review (43 reviews for 25 publications/grants)

Review activity for Acta haematologica. (1)
Review activity for Acta oncologica (1)
Review activity for Annals of lymphoma. (1)
Review activity for BioDrugs. (1)
Review activity for BioDrugs. (2)
Review activity for Blood advances. (2)
Review activity for Blood cancer journal. (1)
Review activity for Cancer communications. (1)
Review activity for Cancer management and research (1)
Review activity for Cancer. (2)
Review activity for Cancers. (11)
Review activity for Clinical case reports. (1)
Review activity for Current oncology. (2)
Review activity for EJHaem. (1)
Review activity for Frontiers in oncology. (2)
Review activity for Hematology (1)
Review activity for JCO oncology practice. (1)
Review activity for Journal for immunotherapy of cancer. (2)
Review activity for Journal of clinical oncology : (1)
Review activity for Leukemia and lymphoma. (1)
Review activity for Medicina. (2)
Review activity for Molecular therapy (1)
Review activity for Nature communications (2)
Review activity for OBM transplantation. (1)
Review activity for Scientific reports. (1)
How many people are using ORCID?